For: | Larrubia JR, Moreno-Cubero E, Miquel J, Sanz-de-Villalobos E. Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control. World J Gastroenterol 2015; 21(12): 3480-3491 [PMID: 25834312 DOI: 10.3748/wjg.v21.i12.3480] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v21/i12/3480.htm |
Number | Citing Articles |
1 |
Richard Barnard, Abha Chopra, Ian James, John Blinco, Mark W Watson, Cassandra B Jabara, Daria Hazuda, Stanley M Lemon, Simon Mallal, Silvana Gaudieri. Primer ID Ultra-Deep Sequencing Reveals Dynamics of drug Resistance-Associated Variants in Breakthrough Hepatitis C Viruses: Relevance to Treatment Outcome and Resistance Screening. Antiviral Therapy 2016; 21(7): 567 doi: 10.3851/IMP3056
|
2 |
Elia Moreno-Cubero, Juan-Ramón Larrubia. Specific CD8<sup>+</sup> T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis. World Journal of Gastroenterology 2016; 22(28): 6469-6483 doi: 10.3748/wjg.v22.i28.6469
|
3 |
Hala S. El-Rebey, Asmaa G. Abdou, Mervat M. Sultan, Shymaa H. Ibrahim, Nanis S. Holah. The Profile and Role of Tumor-infiltrating Lymphocytes in Hepatocellular Carcinoma: An Immunohistochemical Study. Applied Immunohistochemistry & Molecular Morphology 2021; 29(3): 188 doi: 10.1097/PAI.0000000000000865
|
4 |
Ichiro Tamaki, Toshimi Kaido, Shintaro Yagi, Yoshihide Ueda, Etsuro Hatano, Hideaki Okajima, Shinji Uemoto. Spontaneous clearance of hepatitis C virus after liver transplantation: a report of four cases. Surgical Case Reports 2015; 1(1) doi: 10.1186/s40792-015-0127-0
|
5 |
Doaa A. Ghareeb, Eiman H. Elwakeel, Rowaida Khalil, Mina S. Aziz, Maha A. El demellawy. Investigation of the Immunomodulatory effect of Berberis vulgaris on core-pulsed dendritic cell vaccine. BMC Complementary and Alternative Medicine 2016; 16(1) doi: 10.1186/s12906-016-1327-2
|
6 |
Li-Jing Qin, Zhang Lu, Zhong-Hua Zheng, Xiu-Hong Zhong. Research progress of natural products interfering with cell signaling pathway in liver fibrosis. Journal of Asian Natural Products Research 2022; 24(1): 15 doi: 10.1080/10286020.2021.1883003
|
7 |
Saeid Najafi Fard, Ivan Schietroma, Giuseppe Corano Scheri, Noemi Giustini, Sara Serafino, Eugenio Nelson Cavallari, Claudia Pinacchio, Gabriella De Girolamo, Giancarlo Ceccarelli, Carolina Scagnolari, Vincenzo Vullo, Gabriella d’Ettorre. Direct-acting antiviral therapy enhances total CD4+ and CD8+ T-cells responses, but does not alter T-cells activation among HCV mono-infected, and HCV/HIV-1 co-infected patients. Clinics and Research in Hepatology and Gastroenterology 2018; 42(4): 319 doi: 10.1016/j.clinre.2017.11.006
|
8 |
Miguel Jiménez-Pérez, Rocío González-Grande, Pilar España Contreras, Isabel Pinazo Martínez, Jesús de la Cruz Lombardo, Raúl Olmedo Martín. Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistance. World Journal of Gastroenterology 2016; 22(29): 6573-6581 doi: 10.3748/wjg.v22.i29.6573
|
9 |
C. Carlton‐Smith, J. A. Holmes, S. Naggie, A. Lidofsky, G. M. Lauer, A. Y. Kim, R. T. Chung. IFN‐free therapy is associated with restoration of type I IFN response in HIV‐1 patients with acute HCV infection who achieve SVR. Journal of Viral Hepatitis 2018; 25(5): 465 doi: 10.1111/jvh.12836
|
10 |
Grenda Leite Pereira, Andréa Monteiro Tarragô, Walter Luiz Lima Neves, Pedro Vieira da Silva Neto, Priscila Sarmento de Souza, Juliana dos Santos Affonso, Keyla Santos de Sousa, Jéssica Albuquerque da Silva, Allyson Guimarães Costa, Flamir da Silva Victoria, Marilu Barbieri Victoria, Adriana Malheiro. Immunological Dynamics Associated with Direct-Acting Antiviral Therapies in Naive and Experimented HCV Chronic-Infected Patients. Mediators of Inflammation 2019; 2019: 1 doi: 10.1155/2019/4738237
|
11 |
Chao Zhang, Xiao-mei Wang, Shu-ran Li, Trix Twelkmeyer, Wei-hong Wang, Sheng-yuan Zhang, Shu-feng Wang, Ji-zheng Chen, Xia Jin, Yu-zhang Wu, Xin-wen Chen, Sheng-dian Wang, Jun-qi Niu, Hai-rong Chen, Hong Tang. NKG2A is a NK cell exhaustion checkpoint for HCV persistence. Nature Communications 2019; 10(1) doi: 10.1038/s41467-019-09212-y
|
12 |
S. Shrivastava, E. Wilson, B. Poonia, L. Tang, A. Osinusi, A. Kohli, S. Kottilil. Augmentation of hepatitis C virus‐specific immunity and sustained virologic response. Journal of Viral Hepatitis 2017; 24(9): 742 doi: 10.1111/jvh.12702
|
13 |
Noy Ashkenazy, Carol L. Karp, Gaofeng Wang, Carolina Mercado Acosta, Anat Galor. Immunosuppression as a Possible Risk Factor for Interferon Nonresponse in Ocular Surface Squamous Neoplasia. Cornea 2017; 36(4): 506 doi: 10.1097/ICO.0000000000001153
|
14 |
Sylwia Osuch, Karin J. Metzner, Kamila Caraballo Cortés. Reversal of T Cell Exhaustion in Chronic HCV Infection. Viruses 2020; 12(8): 799 doi: 10.3390/v12080799
|
15 |
Pier-Angelo Tovo, Carmelina Calitri, Carlo Scolfaro, Clara Gabiano, Silvia Garazzino. Vertically acquired hepatitis C virus infection: Correlates of transmission and disease progression. World Journal of Gastroenterology 2016; 22(4): 1382-1392 doi: 10.3748/wjg.v22.i4.1382
|
16 |
Jijing Shi, Yuanyuan Li, Wenxian Chang, Xuexiu Zhang, Fu-Sheng Wang. Current progress in host innate and adaptive immunity against hepatitis C virus infection. Hepatology International 2017; 11(4): 374 doi: 10.1007/s12072-017-9805-2
|
17 |
Mohamad S. Hakim, Nofri Rahmadika, Rizka O. A. Jariah. Expressions of inhibitory checkpoint molecules in acute and chronic HBV and HCV infections: Implications for therapeutic monitoring and personalized therapy. Reviews in Medical Virology 2020; 30(2) doi: 10.1002/rmv.2094
|